Contact
QR code for the current URL

Press release Box-ID: 59483

Speedel Pharma AG Hirschgässlein 11 4051 Basel, Switzerland http://www.speedel.com
Contact Nick Miles +41 61 206 40 00
SP
Speedel Pharma AG

FILING FOR U.S. APPROVAL OF RENIN INHIBITOR SPP100 (RASILEZ) IN TREATMENT OF HYPERTENSION BY NOVARTIS

Major milestone for Speedel in its goal to develop renin inhibitors as gold standard therapy over the next decade

(PresseBox) (Basel/Switzerland, )
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.